<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35366371</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1600-0897</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>87</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>American journal of reproductive immunology (New York, N.Y. : 1989)</Title>
          <ISOAbbreviation>Am J Reprod Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Endometrial galectin-3 causes endometriosis by supporting eutopic endometrial cell survival and engraftment in the peritoneal cavity.</ArticleTitle>
        <Pagination>
          <StartPage>e13533</StartPage>
          <MedlinePgn>e13533</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/aji.13533</ELocationID>
        <Abstract>
          <AbstractText Label="PROBLEM" NlmCategory="OBJECTIVE">The pathogenesis of endometriosis remains unclear. Endometrial cells in retrograde menstruation are considered the source of endometriosis; therefore, we hypothesized that the eutopic endometrium may provide clues regarding the pathogenesis. We aimed to clarify the role of eutopic endometrial cells in endometriosis development.</AbstractText>
          <AbstractText Label="METHOD OF STUDY" NlmCategory="METHODS">Eutopic endometrial tissues were obtained from patients with or without endometriosis, and expression of cell surface molecules in eutopic endometrial stromal cells (ESCs) was evaluated via iTRAQ-based proteomic analysis. Based on the results, we focused on galectin-3. Galectin-3 expression in clinical samples was confirmed by immunohistochemistry and Western blot analysis. The concentration of secreted galectin-3 was measured using enzyme-linked immunosorbent assays. Adhesion and migration of ESCs were evaluated by in vitro adhesion and wound healing assays. The cytotoxicity of natural killer cells was measured via calcein release assays. Cell proliferation was measured using the CyQUANT Cell Proliferation Assay Kit.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">iTRAQ analysis revealed that galectin-3 expression was specifically elevated in the ESCs from endometriosis patients. Immunohistochemistry confirmed galectin-3 overexpression in the eutopic endometrium of endometriosis, irrespective of the menstrual phase. Galectin-3 was overexpressed and secreted by the eutopic ESCs from patients with endometriosis compared to that from patients without endometriosis. Galectin-3 expression in ESCs increased adhesion and migration, whereas galectin-3 inhibitors impaired these processes. Galectin-3 reduced the cytotoxicity of natural killer cells toward ESCs, while not affecting cell proliferation.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Galectin-3 promotes peritoneal engraftment of ESCs due to impaired immune surveillance in the peritoneal cavity and increases ESCs adhesion and migration to the peritoneum.</AbstractText>
          <CopyrightInformation>© 2022 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yamashita</LastName>
            <ForeName>Saya</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hashimoto</LastName>
            <ForeName>Kae</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-5836-9359</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sawada</LastName>
            <ForeName>Ikuko</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ogawa</LastName>
            <ForeName>Minori</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakatsuka</LastName>
            <ForeName>Erika</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kawano</LastName>
            <ForeName>Mahiru</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kinose</LastName>
            <ForeName>Yasuto</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kodama</LastName>
            <ForeName>Michiko</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sawada</LastName>
            <ForeName>Kenjiro</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kimura</LastName>
            <ForeName>Tadashi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Denmark</Country>
        <MedlineTA>Am J Reprod Immunol</MedlineTA>
        <NlmUniqueID>8912860</NlmUniqueID>
        <ISSNLinking>1046-7408</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000951">Antigens, Neoplasm</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C081856">LGALS3BP protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000951" MajorTopicYN="N">Antigens, Neoplasm</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="Y">Endometriosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004717" MajorTopicYN="N">Endometrium</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010529" MajorTopicYN="N">Peritoneal Cavity</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017154" MajorTopicYN="N">Stromal Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NK cells</Keyword>
        <Keyword MajorTopicYN="N">endometriosis</Keyword>
        <Keyword MajorTopicYN="N">eutopic endometrium</Keyword>
        <Keyword MajorTopicYN="N">galectin-3</Keyword>
        <Keyword MajorTopicYN="N">peritoneal engraftment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>2</Day>
          <Hour>17</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35366371</ArticleId>
        <ArticleId IdType="doi">10.1111/aji.13533</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Giudice LC, Endometriosis KaoLC. Lancet. 2004;364(9447):1789-1799.</Citation>
        </Reference>
        <Reference>
          <Citation>Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3(2):93-110.43.</Citation>
        </Reference>
        <Reference>
          <Citation>Halme J, Hammond MG, Hulka JF, Raj SG, Talbert LM. Retrograde menstruation in healthy women and in patients with endometriosis. Obstet Gynecol. 1984;64(2):151-154.</Citation>
        </Reference>
        <Reference>
          <Citation>Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril. 2001;75(1):1-10.</Citation>
        </Reference>
        <Reference>
          <Citation>Ahn SH, Monsanto SP, Miller C, Singh SS, Thomas R, Tayade C. Pathophysiology and immune dysfunction in endometriosis. BioMed Res Int. 2015;2015:795976.</Citation>
        </Reference>
        <Reference>
          <Citation>Newlaczyl AU, Yu LG. Galectin-3 - a jack-of-all-trades in cancer. Cancer Lett. 2011;313(2):123-128.</Citation>
        </Reference>
        <Reference>
          <Citation>Hughes RC. Galectins as modulators of cell adhesion. Biochimie. 2001;83(7):667-676.</Citation>
        </Reference>
        <Reference>
          <Citation>Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999;59(16):4148-4154.</Citation>
        </Reference>
        <Reference>
          <Citation>Raz A, Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev. 1987;6(3):433-452.</Citation>
        </Reference>
        <Reference>
          <Citation>Rabinovich GA, Rubinstein N, Toscano MA. Role of galectins in inflammatory and immunomodulatory processes. Biochim Biophys Acta. 2002;1572(2-3):274-284.</Citation>
        </Reference>
        <Reference>
          <Citation>Noël JC, Chapron C, Borghese B, Fayt I, Anaf V. Galectin-3 is overexpressed in various forms of endometriosis. Appl Immunohistochem Mol Morphol. 2011;19(3):253-257.</Citation>
        </Reference>
        <Reference>
          <Citation>Caserta D, Di Benedetto L, Bordi G, D'Ambrosio A, Moscarini M. Levels of galectin-3 and stimulation expressed gene 2 in the peritoneal fluid of women with endometriosis: a pilot study. Gynecol Endocrinol. 2014;30(12):877-880.</Citation>
        </Reference>
        <Reference>
          <Citation>Mattos RM, Machado DE, Perini JA, et al. Galectin-3 plays an important role in endometriosis development and is a target to endometriosis treatment. Mol Cell Endocrinol. 2019;486:1-10.</Citation>
        </Reference>
        <Reference>
          <Citation>Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J Obstet Gynecol. 1975;122(2):262-263.</Citation>
        </Reference>
        <Reference>
          <Citation>Kirk D, Irwin JC. Normal human endometrium in cell culture. Methods Cell Biol. 1980;21B:51-77.</Citation>
        </Reference>
        <Reference>
          <Citation>Lucidi RS, Witz CA, Chrisco M, Binkley PA, Shain SA, Schenken RS. A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells. Fertil Steril. 2005;84(1):16-21.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferreira MC, Witz CA, Hammes LS, et al. Activin A increases invasiveness of endometrial cells in an in vitro model of human peritoneum. Mol Hum Reprod. 2008;14(5):301-307.</Citation>
        </Reference>
        <Reference>
          <Citation>Nakamura K, Sawada K, Kinose Y, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78-92.</Citation>
        </Reference>
        <Reference>
          <Citation>Yoshimura A, Sawada K, Nakamura K, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065.</Citation>
        </Reference>
        <Reference>
          <Citation>Maejima I, Takahashi A, Omori H, et al. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury. EMBO J. 2013;32(17):2336-2347.</Citation>
        </Reference>
        <Reference>
          <Citation>Yamashita M, Kitano S, Aikawa H, et al. A novel method for evaluating antibody-dependent cell-mediated cytotoxicity by flowcytometry using cryopreserved human peripheral blood mononuclear cells. Sci Rep. 2016;6:19772.</Citation>
        </Reference>
        <Reference>
          <Citation>Bastón JI, Barañao RI, Ricci AG, et al. Targeting galectin-1- induced angiogenesis mitigates the severity of endometriosis. J Pathol. 2014;234(3):329-337.</Citation>
        </Reference>
        <Reference>
          <Citation>Vergetaki A, Jeschke U, Vrekoussis T, et al. Galectin-1 over expression in endometriosis and its regulation by neuropeptides (CRH, UCN) indicating its important role in reproduction and inflammation. PLOS ONE. 2014;9(12):e114229.</Citation>
        </Reference>
        <Reference>
          <Citation>Brubel R, Bokor A, Pohl A, et al. Serum galectin-9 as a noninvasive biomarker for the detection of endometriosis and pelvic pain or infertility-related gynecologic disorders. Fertil Steril. 2017;108(6):1016-1025.</Citation>
        </Reference>
        <Reference>
          <Citation>Hisrich BV, Young RB, Sansone AM, et al. Role of human galectins in inflammation and cancer associated with endometriosis. Biolecules. 2020;10:230.</Citation>
        </Reference>
        <Reference>
          <Citation>Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, Koninckx PR. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril. 1991;56(1):45-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Oosterlynck DJ, Meuleman C, Waer M, Vandeputte M, Koninckx PR. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis. Fertil Steril. 1992;58(2):290-295.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu MY, Yang JH, Chao KH, Hwang JL, Yang YS, Ho HN. Increase in the expression of killer cell inhibitory receptors on peritoneal natural killer cells in women with endometriosis. Fertil Steril. 2000;74(6):1187-1191.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang C, Maeda N, Izumiya C, et al. Killer immunoglobulin-like receptor and human leukocyte antigen expression as immunodiagnostic parameters for pelvic endometriosis. Am J Reprod Immunol. 2006;55(2):106-114.</Citation>
        </Reference>
        <Reference>
          <Citation>Matsuoka S, Maeda N, Izumiya C, Yamashita C, Nishimori Y, Fukaya T. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. Am J Reprod Immunol. 2005;53(5):249-254.</Citation>
        </Reference>
        <Reference>
          <Citation>Funamizu A, Fukui A, Kamoi M, et al. Expression of natural cytotoxicity receptors on peritoneal fluid natural killer cell and cytokine production by peritoneal fluid natural killer cell in women with endometriosis. Am J Reprod Immunol. 2014;71(4):359-367.</Citation>
        </Reference>
        <Reference>
          <Citation>Tsuboi S, Sutoh M, Hatakeyama S, et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 2011;30(15):3173-3185.</Citation>
        </Reference>
        <Reference>
          <Citation>Vuong L, Kouverianou E, Rooney CM, et al. An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res. 2019;79(7):1480-1492.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
